CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on March 29, 2006
Clinical Journal of the American Society of Nephrology
© 2006 American Society of Nephrology
doi: 10.2215/CJN.01961205
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.01961205v1
1/3/367    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olgaard, K.
Right arrow Articles by Lewin, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olgaard, K.
Right arrow Articles by Lewin, E.


MINI-REVIEWS

Can Hyperparathyroid Bone Disease Be Arrested or Reversed?

Klaus Olgaard 1 and Ewa Lewin

Nephrological Department P, Rigshospitalet and Nephrological Department B, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark


1 To whom correspondence should be addressed. E-mail: olgaard{at}rh.dk.


   Abstract

Parathyroid hyperplasia, oversecretion of parathyroid hormone (PTH), and hyperparathyroid bone disease are characteristic features of chronic uremia; they develop early in the course of uremia and often in a progressive way. This review focuses on the potential for arrest or regression of hyperparathyroid-induced bone disease. For this purpose, the review addresses investigations that have used bone histology and not investigations that indirectly attempted to demonstrate changes in the skeleton by measurements of bone mineral density or laboratory indices of bone turnover, other than PTH. A prerequisite for inducing regression of the hyperparathyroid bone disease is a significant suppression of PTH secretion or reversal of hyperparathyroidism and uremia. It is concluded, on the basis of paired bone biopsy studies in patients with established hyperparathyroid bone disease, that bone histology can be improved or normalized after treatment that diminishes PTH levels. Oversuppression of PTH levels, however, might lead to adynamic bone disease.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
K. Olgaard and E. Lewin
Use (or misuse) of vitamin D treatment in CKD and dialysis patients: A recent meta-analysis on vitamin D compounds in chronic kidney disease [1] and an editorial comment [2] accompanying this meta-analysis have already been published. We believe that these papers deserve some comments in the interest of the NDT readership
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1786 - 1789.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Society of Nephrology.